366 related articles for article (PubMed ID: 28341962)
41. Mir-1307 regulates cisplatin resistance by targeting Mdm4 in breast cancer expressing wild type P53.
Wang X; Zhu J
Thorac Cancer; 2018 Jun; 9(6):676-683. PubMed ID: 29697201
[TBL] [Abstract][Full Text] [Related]
42. Anillin regulates breast cancer cell migration, growth, and metastasis by non-canonical mechanisms involving control of cell stemness and differentiation.
Wang D; Naydenov NG; Dozmorov MG; Koblinski JE; Ivanov AI
Breast Cancer Res; 2020 Jan; 22(1):3. PubMed ID: 31910867
[TBL] [Abstract][Full Text] [Related]
43. Abnormally elevated USP37 expression in breast cancer stem cells regulates stemness, epithelial-mesenchymal transition and cisplatin sensitivity.
Qin T; Li B; Feng X; Fan S; Liu L; Liu D; Mao J; Lu Y; Yang J; Yu X; Zhang Q; Zhang J; Song B; Li M; Li L
J Exp Clin Cancer Res; 2018 Nov; 37(1):287. PubMed ID: 30482232
[TBL] [Abstract][Full Text] [Related]
44. Resistin induces breast cancer cells epithelial to mesenchymal transition (EMT) and stemness through both adenylyl cyclase-associated protein 1 (CAP1)-dependent and CAP1-independent mechanisms.
Avtanski D; Garcia A; Caraballo B; Thangeswaran P; Marin S; Bianco J; Lavi A; Poretsky L
Cytokine; 2019 Aug; 120():155-164. PubMed ID: 31085453
[TBL] [Abstract][Full Text] [Related]
45. MiR-21 regulates epithelial-mesenchymal transition phenotype and hypoxia-inducible factor-1α expression in third-sphere forming breast cancer stem cell-like cells.
Han M; Wang Y; Liu M; Bi X; Bao J; Zeng N; Zhu Z; Mo Z; Wu C; Chen X
Cancer Sci; 2012 Jun; 103(6):1058-64. PubMed ID: 22435731
[TBL] [Abstract][Full Text] [Related]
46. Mutant p53 Attenuates Oxidative Phosphorylation and Facilitates Cancer Stemness through Downregulating miR-200c-PCK2 Axis in Basal-Like Breast Cancer.
Chao CH; Wang CY; Wang CH; Chen TW; Hsu HY; Huang HW; Li CW; Mai RT
Mol Cancer Res; 2021 Nov; 19(11):1900-1916. PubMed ID: 34312289
[TBL] [Abstract][Full Text] [Related]
47. Metastatic neuroblastoma cancer stem cells exhibit flexible plasticity and adaptive stemness signaling.
Pandian V; Ramraj S; Khan FH; Azim T; Aravindan N
Stem Cell Res Ther; 2015 Feb; 6(1):2. PubMed ID: 25888913
[TBL] [Abstract][Full Text] [Related]
48. A Combined Bioinformatic and Nanoparticle-Based Study Reveal the Role of ABCG2 in the Drug Resistant Breast Cancer.
Huo Q; Yuan J; Zhu T; Li Z; Xie N
Recent Pat Anticancer Drug Discov; 2021; 16(3):393-406. PubMed ID: 33602075
[TBL] [Abstract][Full Text] [Related]
49. A novel miR-34a target, protein kinase D1, stimulates cancer stemness and drug resistance through GSK3/β-catenin signaling in breast cancer.
Kim do Y; Park EY; Chang E; Kang HG; Koo Y; Lee EJ; Ko JY; Kong HK; Chun KH; Park JH
Oncotarget; 2016 Mar; 7(12):14791-802. PubMed ID: 26895471
[TBL] [Abstract][Full Text] [Related]
50. NANOGP8 is the key regulator of stemness, EMT, Wnt pathway, chemoresistance, and other malignant phenotypes in gastric cancer cells.
Ma X; Wang B; Wang X; Luo Y; Fan W
PLoS One; 2018; 13(4):e0192436. PubMed ID: 29689047
[TBL] [Abstract][Full Text] [Related]
51. Determination of the target proteins in chemotherapy resistant breast cancer stem cell-like cells by protein array.
Kars MD; Yıldırım G
Eur J Pharmacol; 2019 Apr; 848():23-29. PubMed ID: 30707960
[TBL] [Abstract][Full Text] [Related]
52. APC selectively mediates response to chemotherapeutic agents in breast cancer.
VanKlompenberg MK; Bedalov CO; Soto KF; Prosperi JR
BMC Cancer; 2015 Jun; 15():457. PubMed ID: 26049416
[TBL] [Abstract][Full Text] [Related]
53. Anti-metastasis activity of curcumin against breast cancer via the inhibition of stem cell-like properties and EMT.
Hu C; Li M; Guo T; Wang S; Huang W; Yang K; Liao Z; Wang J; Zhang F; Wang H
Phytomedicine; 2019 May; 58():152740. PubMed ID: 31005718
[TBL] [Abstract][Full Text] [Related]
54. miR-375 inhibits cancer stem cell phenotype and tamoxifen resistance by degrading HOXB3 in human ER-positive breast cancer.
Fu H; Fu L; Xie C; Zuo WS; Liu YS; Zheng MZ; Yu JM
Oncol Rep; 2017 Feb; 37(2):1093-1099. PubMed ID: 28075453
[TBL] [Abstract][Full Text] [Related]
55. Inhibition of Cdk2 kinase activity selectively targets the CD44⁺/CD24⁻/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells.
Opyrchal M; Salisbury JL; Iankov I; Goetz MP; McCubrey J; Gambino MW; Malatino L; Puccia G; Ingle JN; Galanis E; D'Assoro AB
Int J Oncol; 2014 Sep; 45(3):1193-9. PubMed ID: 24970653
[TBL] [Abstract][Full Text] [Related]
56. USP37 downregulation elevates the Chemical Sensitivity of Human Breast Cancer Cells to Adriamycin.
Qin T; Cui XY; Xiu H; Huang C; Sun ZN; Xu XM; Li LH; Yue L
Int J Med Sci; 2021; 18(2):325-334. PubMed ID: 33390801
[No Abstract] [Full Text] [Related]
57. Increased JNK1 signaling pathway is responsible for ABCG2-mediated multidrug resistance in human colon cancer.
Zhu MM; Tong JL; Xu Q; Nie F; Xu XT; Xiao SD; Ran ZH
PLoS One; 2012; 7(8):e41763. PubMed ID: 22870247
[TBL] [Abstract][Full Text] [Related]
58. MicroRNA-155-5p promotes tumor progression and contributes to paclitaxel resistance via TP53INP1 in human breast cancer.
Li Y; Zhang L; Dong Z; Xu H; Yan L; Wang W; Yang Q; Chen C
Pathol Res Pract; 2021 Apr; 220():153405. PubMed ID: 33756128
[TBL] [Abstract][Full Text] [Related]
59. Activity of ABCG2 Is Regulated by Its Expression and Localization in DHT and Cyclopamine-Treated Breast Cancer Cells.
Chua VY; Larma I; Harvey J; Thomas MA; Bentel JM
J Cell Biochem; 2016 Oct; 117(10):2249-59. PubMed ID: 26917208
[TBL] [Abstract][Full Text] [Related]
60. miR-155 increases stemness and decitabine resistance in triple-negative breast cancer cells by inhibiting TSPAN5.
Yang LW; Wu XJ; Liang Y; Ye GQ; Che YC; Wu XZ; Zhu XJ; Fan HL; Fan XP; Xu JF
Mol Carcinog; 2020 Apr; 59(4):447-461. PubMed ID: 32096299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
